Pyrazinobenzodiazepines as potent nonpeptide vasopressin receptor antagonists

Letters in Drug Design and Discovery

Volumn 2, Issue 3, 2005, Pages 219-223

  Matthews, Jay M ^a,b   Hlasta, Dennis J ^a   Andrade Gordon, Patricia ^a   Demarest, Keith T ^b   Ericson, Eric ^b   Gunnet, Joseph W ^b   Hageman, William ^a   Look, Richard ^b   Moore, John B ^b   Maryanoff, Bruce E ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JNJ 16240198; LIXIVAPTAN; PYRAZINOBENZODIAZEPINE DERIVATIVE; RWJ 659834; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS;

EID: 21044457953     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570180053765183     Document Type: Article

References (23)

1. (a) Albright, J. D.; Chan, P. S. Curr. Pharm. Design 1997, 3, 615.;
2. (b) Thibonnier, M.; Conarty, D. M.; Preston, J. A. Wilkins, P. L.; Berti-Mattera, L. N.; Mattera, R. Adv. Exp. Med. Biol. 1998, 449, 251.;
3. (c) Trybulski, E. J. Annu. Rep. Med. Chem. 2001, 36, 159.;
4. (d) Thibonnier, M. Expert Opin. Invest. Drugs 1998, 7, 729.;
5. (e) Paranjape, S. B.; Thibonnier, M. Expert Opin. Invest. Drugs 2001, 10, 825.
6. (a) Dyatkin, A. B.; Hoekstra, W. J.; Hlasta, D.; Andrade-Gordon, P.; de Garavilla, L.; Demarest, K. T.; Gunnet, J. W.; Hageman, W.; Look, R.; Maryanoff, B. E. Bioorg. Med. Chem. Lett. 2002, 12, 3081.;
7. (b) Matthews, J. M.; Hoekstra, W. J.; Andrade-Gordon, P.; de Garavilla, L.; Demarest, K. T.; Ericson, E.; Greco, M. N.; Gunnet, J. W.; Hageman, W.; Hecker, L. R.; Look, R.; Moore, J. B.; Maryanoff, B. E. Bioorg. Med. Chem. Lett. 2003, 13, 753.;
8. (c) Matthews, J. M.; Hoekstra, W. J.; Dyatkin, A. B.; Hecker, L. R.; Hlasta, D. J.; Poulter, B. L.; Andrade-Gordon, P.; de Garavilla, L.; Demarest, K. T.; Ericson, E.; Gunnel, J. W.; Hageman, W.; Look, R.; Moore, J. B.; Reynolds, C. R.; Maryanoff, B. E. Bioorg. Med. Chem. Lett. 2004, 14, 2747.;
9. (d) Dyatkin, A. B.; Freedman, T. B.; Cao, X.; Dukor, R. K.; Maryanoff, B. E.; Maryanoff, C. A.; Matthews, J. M.; Shah, R. D.; Nafie, L. A. Chirality 2002, 14, 215.;
10. (e) Matthews, J. M.; Dyatkin, A. B.; Evangelislo, M.; Gaulhier, D. A.; Hecker, L. R.; Hoekstra, W. J.; Poulter, B. L.; Maryanoff, B. E. Tetrahedron: Asymmetry 2004, 15, 1259.
11. (a) Oprea, T. I. J. Comp.-Aided Mol. Design 2000, 14, 251.;
12. (b) Walters, W. Patrick; A.; Murcko, M. A. Curr. Opin. Chem. Biol. 1999, 3, 384.
13. a = 11.9 (SciFinder, Advanced Chemistry Development software, Solaris v4.67).
14. Olofson, R. A.; Martz, J. T.; Senet, J. P.; Piteau, M.; Malfroot, T. J. Org. Chem. 1984, 49, 2081.
15. The X-ray crystal structure of (S)-(+)-4a, as a salt with dibenzoyl-D-tartaric acid, confirmed this absolute configuration [2e].
16. (R)-(+)-3 has the same spatial arrangement at the stereogenic center as does 1; however, the stereochemical descriptor for the absolute configuration of (+)-3 ["R"] differs from that of 1 ["S"] because of the Cahn-Ingold-Prelog priority rules: Cahn, R. S.; Ingold, C.; Prelog, V. Angew. Chem., Int. Ed. 1966, 5, 385.
17. 3H]-AVP.
18. 2) concentrations were measured.
19. 2 (cAMP) receptors in transfected HEK-293 cells.
20. 1b or oxytocin receptors in transfected HEK-293 cells.
21. Ogawa, H.; Yamashita, H.; Kondo, K.; Yamamura, Y.; Miyamoto, H.; Kan, K.; Kitano, K.; Tanaka, M.; Nakaya, K.; Nakamura, S.; Mori, T.; Tominaga, M.; Yabuuchi, Y. J. Med. Chem. 1996, 39, 3547.
22. Albright, J. D.; Reich, M. F.; Santos, E. G. D.; Dusza, J. P.; Sum, F. W.; Venkatesan, A. M.; Coupet, J.; Chan, P. S.; Ru, X.; Mazandarani, H.; Bailey, T. J. Med. Chem. 1998, 41, 2442.
23. a = 6.89/12.7.